TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functioning living or deceased donor allograft \>=1 year post-transplantation~* Baseline (screening) biopsy showing Grade II or III interstitial fibrosis/tubular atrophy (IF/TA) (\>=25% IF/TA)~* Progressive loss in kidney function observed after the first year post-transplant, defined as an estimated glomerular filtration rate (eGFR) decline of ≥3 mL/min/year for at least 24 months prior to screening, with a minimum of 2 documented measurements per year (minimum of 4 documented measurements in the 24-month period, performed at least 1 month apart)~* An eGFR \>=30 mL/min/1.73 m\^2 for a period of 6 months up to screening~* Stable standard of care concomitant medication for 3 months prior to screening~* Participant is male or female, \>=18 years of age~Exclusion Criteria:~* Recipient of multi-organ transplant (with the exception of repeated kidney transplant recipients, and/or corneal transplant recipients)~* Screening biopsy shows evidence of significant active antibody-mediated rejection that may affect the conduct of the study (eg, require change in treatment) according to the Principal Investigator (PI)~* Screening biopsy shows evidence of T cell-mediated rejection that may affect the conduct of the study (eg, require change in treatment) according to the PI~* Screening biopsy shows evidence of de novo or recurrent glomerular disease that may affect the conduct of the study (eg, require change in treatment) according to the PI~* Proteinuria ≥1500 mg/g at screening~* Participant who has a history of biopsy-proven acute rejection or treatment for suspected acute rejection within 3 months prior to screening~* Participant has had major surgery (including joint surgery) within 6 months prior to screening, or has planned surgery within 6 months after the last dose of investigational medicinal product (IMP)~* Participant has a current diagnosis of foot ulcer or diagnosis of chronic diabetic ulcer or history of delayed wound healing~* Participant has taken concomitant medication of sirolimus or everolimus within 3 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zampilimab Cohorts (Type: EXPERIMENTAL): Participants will be randomized to receive zampilimab (UCB7858).
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm will receive matching Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Minor Traumatic Brain Injury : MRI Examination of Consequences and Social Insertion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who answered to psychological questionnaires 3 month after mTBI~* Patients with mTBI according to European Federation of Neurological Societies~* Initial CT scan indication according to 2012 French Society of Emergency Medicine and European Federation of Neurological Societies~* Health insurance~* Written consent~Exclusion Criteria:~* Under 18 years~* Psychiatric or neurologic history with long term treatment~* Hospitalization due to extra-cranial wounds or intoxication (except alcool)~* MTBI due to aggression~* MRI contraindication~* Inability to understand french language~* Pregnant or breastfeeding women~* Incapacitated patients in accordance with article L 1121-5 to L1121-8 of the public health code~* Patients in another study's exclusion time~* Inability to have a follow-up~* Patients who can't be reached in case of emergency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Symptomatic group at three month (Type: EXPERIMENTAL): Rivermead Post-Concussion Syndrome \>= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire
- Asymptomatic group at three month (Type: EXPERIMENTAL): Rivermead Post-Concussion Syndrome \< 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV infection must be documented by positive anti-HCV antibody using a third-generation enzyme immunoassay and persistent detection of HCV RNA in the blood for at least 6 months.~* Participants must be infected with HCV genotype 1 (line probe assay; INNO-LiPA HCV II, Innogenetics) and maybe treatment-naïve or treatment-experienced (treatment experienced specifically means prior treatment with interferon, standard or pegylated, with or without ribavirin with therapy stopped \> 6 months prior to screening).~* Eligible participants must have had alanine aminotransferase and aspartate aminotransferase \< 5 x upper limit of normal (ULN), plasma HCV RNA \> 5 log10 international units (IU)/milliliter (mL), and have had no clinical or laboratory evidence of hepatic decompensation for inclusion (must have platelets \> 100,000/cubic millimeter \[mm\^3\], total bilirubin \< 1.5 x ULN, prothrombin time \< 1.5 x ULN, or albumin \> 3.0 grams/deciliter \[g/dL\] for inclusion).~* Women were eligible if not pregnant or breast-feeding.~* Women of childbearing potential (that is, not surgically sterile or confirmed post menopausal) must have had confirmed negative pregnancy tests. All participants must practice a medically acceptable form of contraception.~Exclusion Criteria:~* Human immunodeficiency virus or hepatitis B virus co-infection known cirrhosis.~* Prior history of clinical hepatic decompensation (ascites, jaundice, encephalopathy, or variceal hemorrhage), alcoholic or other forms of chronic liver disease, evidence of hepatocellular carcinoma (α-fetoprotein \> 50 nanograms/mL), creatinine clearance \< 80 mL/minute (using Cockcroft-Gault equation), hemoglobin \< 10 g/dL, neutrophils \< 1500/mm\^3, and abnormal thyroid function tests (thyroid stimulating hormone \> 2.5 microIU/mL, free T4 \> ULN), or, a positive test result for illicit drugs, alcohol, or drug abuse within the past 12 months.~* Participants who have had significant gastrointestinal, thyroid, renal, cardiovascular, pulmonary, oncologic, or neurological disease, or who are currently receiving immunomodulators (corticosteroids), investigational, nephrotoxic or hepatotoxic drugs (for example, phenytoin, carbamazepine, isonicotinic acid hydrazide, azole anti-fungal agents such as ketoconazole, and aminoglycoside antibiotics), non-steroidal anti-inflammatory agents, ibuprofen or acetaminophen (on a daily basis) will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Males and females~* Indication for laparoscopic nephrectomy~Exclusion Criteria:~* Blood donation within the last month~* Lack of wish to participate~* eGFR\< 15ml/min~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Voluven (Hydroxyethyl starch 130/0,4) (Type: ACTIVE_COMPARATOR): Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
- Sodium Chloride 9mg/ml (Type: PLACEBO_COMPARATOR): Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed Diagnosis of HCC~2. Has a Globo-H or SSEA-3 positive tumor as determined by IHC~3. Never received TACE/ chemotherapy/ radiotherapy or targeted agents prior to this study.~4. Patients should be in BCLC clinical stage B (multinodular asymptomatic tumors without extra-hepatic spread or portal vein invasion) with or without unilateral secondary or tertiary branches of portal vein invasion.~5. Child-Pugh functional class A or B.~6. GALNT14- rs9679162 non TT genotype~7. At least 1 measurable lesion must be present.~8. ECOG performance status 0 to 1.~9. Age \> 20 years~10. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial and 4 weeks after last treatment~11. Informed consent must be obtained prior to perform any study procedure.~12. Total bilirubin \< 3.0 mg/dL with no evidence of biliary tract obstruction.~13. Appropriate Serum alanine aminotransferase, aspartate aminotransferase, Absolute neutrophil count, Platelets and Serum creatinine~(16) Antiviral treatment for hepatitis B or C is allowed except for interferon.~Exclusion Criteria:~1. BCLC stage A.~2. Presence of extrahepatic metastasis or main portal vein thrombosis.~3. Child-Pugh score = C.~4. Significant cardiac disease as determined by investigator.~5. Serious bacterial infection requiring systemic antibiotics.~6. Pregnancy~7. Expected non-compliance.~8. Uncontrolled illness including, but not limited to, ongoing infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness.~9. Bleeding esophageal or gastric varices within three months without ligation or sclerosis injection therapy.~10. Subjects with known HIV infection.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE alone arm (Type: ACTIVE_COMPARATOR): TACE (Transarterial Chemoembolization)
- adagloxad simolenin arm (Type: EXPERIMENTAL): TACE plus adagloxad simolenin/OBI-821 adjuvant therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with cystic fibrosis confirmed by sweat or genetic test~* Patient with clinical signs of exacerbation (increased cough, sputum (abundance, purulence), fever, anorexia, weight loss and FEV1) or acute exacerbations (defined at the clinician's discretion )~* FEV1 ≥ 25%~* Pseudomonas aeruginosa chronic carriers (defined by at least two antipyocyanic precipitation arcs or at least 3 successive positive ECBCs over a period of 18 months)~* Patient who received at least 1 IV course of antibiotics in the 18 months prior to inclusion.~Exclusion Criteria:~* Severe exacerbation (requiring hospitalization due to severe amputation of FEV 1, oxygen deficiency, or severe impairment of general health).~* Patient with 3rd antibiotic therapy (triple therapy)~* Patient colonized in Burkholderia cepacia~* Patient colonized by an atypical mycobacterium~* Patient with pulmonary transplant or transplant~  * chronic tinnitus~ * patient using hearing aid~* Hypersensitivity to tobramycin and other antibiotics of the aminoglycoside family~* Cirrhosis of Grades B and C according to the Child-Pugh Classification~* Myasthenia gravis~* Simultaneous administration of another aminoglycoside~* Renal failure~* Recent history of severe hemoptysis (within 2 months before inclusion)~* Patient participating simultaneously in another clinical study conducted on a drug for the duration of its participation in this research

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard cure (Type: EXPERIMENTAL): Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
- Short cure (Type: EXPERIMENTAL): antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive Shunt Quantification in Interatrial Communication

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* cooperate patients over 18 years, having a OS ASD with an indication of interventional closure according to the European Cardiology society guidelines of 2010.~* Patients with significant shunt (signs of right ventricular volume overload) and Pulmonary Vascular Resistance (PVR) \<5WU~* ASD, regardless the size, with suspicion of paradoxal embolism~* Patients with PVR \> or egal 5 WU but \<2/3 Systemic Vascular Resistance or Pulmonary Arterial Pressure \< 2/3 systemic pressure and evidence of net Left-to Right shunt (Qp/Qs \> 1,5)~* with the French Social Security System~Exclusion Criteria:~* Pregnant women and breastfeeding women~* Difficulties of cooperation (patient under assisted ventilation)~* Chronic Obstructive Pulmonary disease or respiratory failure~* Complex congenital heart disease~* Antiplatelet contraindication~* Patients under protection, vulnerable patients~* No consent~* Contraindication of the non-invasive devices~* Physioflow (Manatec, France): patients with pacemaker, with a cardiorespiratory support and assistance, severe aortic insufficiency~* Innocor (Innovision, Odense, Denmark): to our knowledge, and according to the user instructions, there is no contraindication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with Atrial septal defect type Ostium Secundum (Type: EXPERIMENTAL): patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Anesthesia, Using Bispectral Index as the Control Variable, During Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* liver transplantation~Exclusion Criteria:~* pregnant women~* allergy to propofol or remifentanil,~* neurological or muscular disorder,~* liver encephalopathy,~* patients taking psychotropic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Manual administration
- 2 (Type: EXPERIMENTAL): Closed-loop administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Evidence of chronotropic incompetence on exercise or pharmacological stress test defined as the inability to achieve 85% or greater of Age-predicted heart rate reserve (APMHR)~* Legal status to give informed consent specific to state and national law.~* Planned for PPM implantation and meets current guidelines for PPM therapy.~Exclusion Criteria:~* Inability to give informed consent~* Inability to comply with the follow-up visit schedule.~* Unable to participate in stress testing (exercise or pharmacological).~* Previous PPM implantation~* A life expectancy of less than 12 months per physician discretion~* Enrolled in any concurrent study, without Boston Scientific written approval.~* Pregnancy~* Unstable chest pain~* Stroke within 30 days~* Heart attack within 90 days~* Stress Test Exclusion Criteria: No evidence of Chronotropic incompetence on exercise or pharmacological stress test, defined as the ability to achieve 85% or greater of APMHR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blended Sensor Optimization (BSO) (Type: EXPERIMENTAL): Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
- Accelerometer Alone (AA) (Type: SHAM_COMPARATOR): Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status ECOG-WHO 0, 1 or 2~* Metastatic renal cancer~* Patient candidate to everolimus treatment~* signed written informed consent~* fertile women with adequate contraception during the study and until 8 weeks after stopping treatment~Exclusion Criteria:~* Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)~* History of immune deficiency~* Hypersensitivity against rapamycin and derived~* Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years~* Active autoimmune diseases, HIV, hepatitis C or B virus~* Patients with any medical or psychiatric condition or disease,~* Patients under guardianship, curatorship or under the protection of justice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biological samples (Type: EXPERIMENTAL): Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any male age 40 or older~* Scheduled to undergo one of the planned surgeries (thoracic, general, or urologic)~* Ability to give informed consent~Exclusion Criteria:~* Current use of alpha blocker~* Current use of a strong CYP 3A4 inhibitors~* Any allergy to tamsulosin, alpha-blocker medication class, or anaphylaxis allergy to sulfate containing medications~* Patients with any upcoming surgery for cataracts~* Currently enrolled in a clinical trial~* Inability to give informed consent

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tamsulosin Group (Type: EXPERIMENTAL): Subjects will receive:~1. 0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~2. education about signs and symptoms of urinary retention
- Education Group (Type: ACTIVE_COMPARATOR): Subjects will receive:~1) education about signs and symptoms of urinary retention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues